Thyroid Cancer Clinical Trial
Cytological examination of punctured lymph nodes is the gold standard for confirming
metastatic lymph node spread of differentiated thyroid cancers. In order to increase the
diagnostic sensitivity of fine-needle cyto-punctured lymph nodes, an assessment of Tg levels
of the aspirate could be included. Although this technique has been well proven, many
uncertainties remain, especially with regards to a pathological cut-off value and its
clinical utility when the thyroid is still intact. This uncertainty is mainly due to
discordancy between low Tg levels found in cytopunctured lymph nodes with normal cytology,
and their final histopathological analyses.
To eliminate this uncertainty, cyto-punction will be performed intra-operatively after
localizing and isolating the target lymph nodes for assessment of cytology and Tg values. The
thyroid gland might be present or absent (already operated) depending on the case. Finally,
the cyto-punctured lymph nodes will be excised for complete histopathological analysis. In
order to determine whether the Tg values are appropriate in cases where the thyroid is
intact, a control group has been included (First operation for thyroid cancer or benign
pathology). To eliminate the possible iatrogenic risks of lymph node dissection and resection
in patients for whom it is not indicated, only lymph nodes found along the incision path for
neuromonitoring of the recurrent laryngeal nerve (performed systematically) will be analysed
and excised.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05774535 -
Prospective, Observational Study on the Carotid Intima-media Thickness in Patients Undergoing Thyroid Surgery
|
||
| Withdrawn |
NCT04224792 -
Effects of Exercise Training on Fatigue in Thyroid Cancer Survivors
|
N/A | |
| Completed |
NCT01728623 -
A Study of E7080 in Subjects With Advanced Thyroid Cancer
|
Phase 2 | |
| Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 | |
| Completed |
NCT02911155 -
Cancer and Other Disease Risks in U.S. Nuclear Medicine Technologists
|
||
| Recruiting |
NCT05025046 -
NGS-based Thyroscan Genomic Classifier in the Diagnosis of Thyroid Nodules
|
||
| Not yet recruiting |
NCT03978351 -
The Role of Midkine in Diagnosis of Thyroid Cancer
|
||
| Completed |
NCT02658513 -
Evaluation of Lancet Blood Sampling for Radioiodine Dosimetry in Thyroid Cancer
|
||
| Terminated |
NCT02628535 -
Safety Study of MGD009 in B7-H3-expressing Tumors
|
Phase 1 | |
| Withdrawn |
NCT01994200 -
Developing and Implementing an Interdisciplinary Team-Based Care Approach (ITCA-ThyCa) for Thyroid Cancer Patients
|
Phase 1/Phase 2 | |
| Completed |
NCT02375451 -
Effect of Childhood Radioiodine Therapy on Salivary Function
|
N/A | |
| Terminated |
NCT01403324 -
Comparison of Dosimetry After rhTSH or Withdrawal of Thyroid Hormone in Metastatic or Locally Advanced Thyroid Cancer
|
N/A | |
| Completed |
NCT00970359 -
Reacquisition of Radioactive Iodine (RAI) Uptake of RAI-Refractory Metastatic Thyroid Cancers by Pretreatment With the Selective MEK Inhibitor AZD6244
|
N/A | |
| Completed |
NCT00439478 -
Dental Safety Profile of High-Dose Radioiodine Therapy
|
Phase 4 | |
| Completed |
NCT00223158 -
Evaluation Study of L-T3 Utility in the Follow-up of Patients With Thyroid Cancer
|
N/A | |
| Active, not recruiting |
NCT04544111 -
PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer
|
Phase 2 | |
| Completed |
NCT04876287 -
Salivary dysfuncTion After Radioiodine Treatment
|
||
| Recruiting |
NCT06073223 -
Intervention to Decrease Overtreatment of Patients With Low-risk Thyroid Cancer
|
N/A | |
| Recruiting |
NCT06037174 -
Comparison of Quality of Life in Patients With Differentiated Thyroid Carcinoma Undergoing Different Surgery
|
||
| Recruiting |
NCT04952493 -
Anlotinib or Penpulimab in Combination With RAI for DTC
|
Phase 2 |